Merck Reports observational Data for Antisense oligonucleotide in Alzheimer's disease

Merck today announced observational results for antisense oligonucleotide in patients with Alzheimer's disease. The study demonstrated that antisense oligonucleotide achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of Alzheimer's disease and support the continued development of antisense oligonucleotide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.